Apellis Pharmaceuticals Inc (APLS) Insider Trading
- $23,844,337.28
- $105,410,074.36
- Feb. 11, 2025
- Alec Machiels
Trader Name | Date | Title | Amount | Price | Type | Total Value |
---|---|---|---|---|---|---|
Feb. 11, 2025 | Insider | 363 | $28.54 | Sell | $10,360.02 | |
Jan. 29, 2025 | CFO | 546 | $29.52 | Sell | $16,117.92 | |
Jan. 29, 2025 | General Counsel | 695 | $29.52 | Sell | $20,516.40 | |
Jan. 29, 2025 | Insider | 825 | $29.52 | Sell | $24,354.00 | |
Jan. 29, 2025 | CEO | 2,824 | $29.52 | Sell | $83,364.48 | |
Jan. 22, 2025 | CEO | 13,551 | $30.43 | Sell | $412,356.93 | |
Jan. 22, 2025 | CAO | 1,096 | $30.43 | Sell | $33,351.28 | |
Jan. 22, 2025 | CFO | 3,088 | $30.43 | Sell | $93,967.84 | |
Jan. 22, 2025 | General Counsel | 3,323 | $30.43 | Sell | $101,118.89 | |
Jan. 22, 2025 | Insider | 3,948 | $30.43 | Sell | $120,137.64 | |
Jan. 17, 2025 | CEO | 6,007 | $29.96 | Sell | $179,969.72 | |
Jan. 17, 2025 | Insider | 2,145 | $29.96 | Sell | $64,264.20 | |
Jan. 17, 2025 | CAO | 715 | $29.96 | Sell | $21,421.40 | |
Jan. 17, 2025 | General Counsel | 2,201 | $29.96 | Sell | $65,941.96 | |
Jan. 17, 2025 | CFO | 1,730 | $29.96 | Sell | $51,830.80 | |
Jan. 13, 2025 | CAO | 783 | $28.70 | Sell | $22,472.10 | |
Jan. 13, 2025 | Insider | 264 | $28.70 | Sell | $7,576.80 | |
Jan. 13, 2025 | CEO | 6,247 | $28.70 | Sell | $179,288.90 | |
Jan. 13, 2025 | General Counsel | 4,965 | $28.70 | Sell | $142,495.50 | |
Jan. 13, 2025 | CFO | 2,170 | $28.70 | Sell | $62,279.00 | |
Jan. 6, 2025 | Insider | 2,816 | $33.81 | Sell | $95,208.96 | |
Dec. 23, 2024 | Insider | 63 | $33.09 | Sell | $2,084.67 | |
Sept. 16, 2024 | Director | 37,000 | $36.23 | Sell | $1,340,510.00 | |
June 21, 2024 | Director | 37,000 | $39.24 | Sell | $1,451,880.00 | |
May 8, 2024 | Insider | 78,907 | $42.35 | Sell | $3,341,711.45 | |
April 8, 2024 | Insider | 69,107 | $54.17 | Sell | $3,743,526.19 | |
April 1, 2024 | CFO | 4,000 | $58.66 | Sell | $234,640.00 | |
March 19, 2024 | Director | 18,681 | $57.18 | Sell | $1,068,179.58 | |
March 18, 2024 | Insider | 9,913 | $56.90 | Sell | $564,049.70 | |
March 15, 2024 | CAO | 184 | $56.46 | Sell | $10,388.64 | |
March 13, 2024 | Insider | 11,220 | $57.56 | Sell | $645,823.20 | |
March 1, 2024 | CFO | 6,000 | $63.22 | Sell | $379,320.00 | |
March 1, 2024 | CEO | 250,000 | $64.11 | Sell | $16,027,500.00 | |
Feb. 12, 2024 | CEO | 3,962 | $67.77 | Sell | $268,504.74 | |
Feb. 12, 2024 | General Counsel | 781 | $67.77 | Sell | $52,928.37 | |
Feb. 12, 2024 | Insider | 1,148 | $67.77 | Sell | $77,799.96 | |
Feb. 12, 2024 | CFO | 1,431 | $67.77 | Sell | $96,978.87 | |
Jan. 29, 2024 | General Counsel | 906 | $64.14 | Sell | $58,110.84 | |
Jan. 29, 2024 | CEO | 2,843 | $64.14 | Sell | $182,350.02 | |
Jan. 29, 2024 | Insider | 835 | $64.14 | Sell | $53,556.90 | |
Jan. 22, 2024 | General Counsel | 4,184 | $65.00 | Sell | $271,960.00 | |
Jan. 22, 2024 | CEO | 13,431 | $65.00 | Sell | $873,015.00 | |
Jan. 22, 2024 | CAO | 1,061 | $65.00 | Sell | $68,965.00 | |
Jan. 22, 2024 | Insider | 3,413 | $65.00 | Sell | $221,845.00 | |
Jan. 22, 2024 | CFO | 3,551 | $65.00 | Sell | $230,815.00 | |
Jan. 16, 2024 | General Counsel | 4,240 | $66.81 | Sell | $283,274.40 | |
Jan. 16, 2024 | CFO | 2,235 | $66.81 | Sell | $149,320.35 | |
Jan. 16, 2024 | CAO | 864 | $66.81 | Sell | $57,723.84 | |
Jan. 16, 2024 | CEO | 7,851 | $66.81 | Sell | $524,525.31 | |
Jan. 16, 2024 | Insider | 438 | $66.81 | Sell | $29,262.78 |
Insiders are both buying and selling Apellis Pharmaceuticals Inc stock.
The insider traders at Apellis Pharmaceuticals Inc are: Alec Machiels, Cedric Francois, Federico Grossi, Pascal Deschatelets, David O Watson, A. Sinclair Dunlop, Mark Jeffrey Delong, Timothy Eugene Sullivan, Adam J Townsend, Lukas Scheibler, James George Chopas, Jeffrey Eisele, Nur Nicholson, Nicole D Perry, Morningside Venture Investment, Karen Lewis, Caroline Baumal, Machiels Alec, Global Strategic Fund I Venbio, Deschatelets Pascal, Victoria L Brown, and Victoria L. Brown
The most active insider trader at Apellis Pharmaceuticals Inc is Alec Machiels with 30 trades.
Cedric Francois has sold the most Apellis Pharmaceuticals Inc stock with a total value of $35,626,981.58.
Morningside Venture Investment has bought the most Apellis Pharmaceuticals Inc stock with a total value of $31,651,764.04.
The most recent insider trade for Apellis Pharmaceuticals Inc was on Feb. 11, 2025.
The single biggest insider buy for Apellis Pharmaceuticals Inc was from Morningside Venture Investment with a total value of $10,000,000.00 on Nov. 18, 2021.
The single biggest insider sell for Apellis Pharmaceuticals Inc was from Cedric Francois with a total value of $16,027,500.00 on March 1, 2024.